Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli

Israel Medical Association Journal

Volumn 7, Issue 5, 2005, Pages 298-301

  Bishara, Jihad ^a   Livne, Gilat ^b,c   Ashkenazi, Shai ^b,c   Levy, Itzhak ^b,c   Pitlik, Silvio ^a   Ofir, Orit ^a   Lev, Bruria ^a   Samra, Zmira ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antibiotics; Escherichia coli; Extended spectrum lactamase; Klebsiella pneumoniae; Resistance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; ERTAPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONFIDENCE INTERVAL; CONTROLLED STUDY; ESCHERICHIA COLI; ISRAEL; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AMIKACIN; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BETA-LACTAMASES; CHILD; CIPROFLOXACIN; CLAVULANIC ACID; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; ESCHERICHIA COLI; HUMANS; ISRAEL; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; ODDS RATIO; PENICILLANIC ACID; PIPERACILLIN; PREVALENCE;

EID: 18744394060     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Livermore DM. β-lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 1998; 41:25-41
2. Garau J. Beta-lactamases: current situation and clinical importance. Intensive Care Med 1994;20:S5-9
3. Menashe G, Borer A, Yagupsky P, et al. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 2001;33:188-93.
4. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39(6):2206-12.
5. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004;23:163-7.
6. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000;6(9):460-3.
7. Paterson DL, Von Ko W, Gottberg A, et al. In vitro susceptibility and clinical outcome of bacteremia due to extended-spectrum beta-lactamase producing Klebsiella pneumoniae. Clin Infect Dis 1998;27:956.
8. Navov-Venezia S, Hammer-Munz O, Schwartz D, Turner D, Kuzmenko B, Carmeli Y. Occurrence and phenotypic of extended-spectrum β-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests. J Clin Microbiol 2003;41:155-8.
9. Borer A, Gilad J, Menashe G, Peled N, Reisenberg K, Schlaeffer F. Extended-spectrum beta-lactamase-producing Enterobacteriaceae strains in community-acquired bacteremia in southern Israel. Med Sci Monit 2002;8:44-7.
10. Schwaber MJ, Navon-Venezia S, Scwartz D, Carmeli Y. High levels of antimicrobials cross-resistance among ESBL-producing enterobactereaceae. Presented at the Annual Meeting of The Israeli Society of Infectious Diseases, 2004.
11. Colodner R, Raz R, Chazan B, Sakran W. Susceptibility pattern of extended-spectrum β-lactamase producing bacteria from inpatients to five antimicrobials drugs in a community hospital in northern Israel [Letter]. Int J Antimicrob Agents 2004;24(4):409-10.
12. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard M2-A7. Villanova, PA: NCCLS, 2000
13. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of stains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas and the Western Pacific region. Clin Infect Dis 2001;32(Suppl 2):S94-103.
14. Sader HS, Jones RN, Andrade-Baiocchi S, Biedenbach DJ. SENTRY Participants Group (Latin America). Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diag Microbiol Infect Dis 2002;44:273-80.
15. Rennie RP, Jones RN, Mutnick AH. SENTRY Program study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report of the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000) Diagn Microbiol Infect Dis 2003;45:287-93.
16. Du B, Long Y, Liu H, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factor and clinical outcome. Intensive Care Med 2002;28:1718-23.
17. The Microbiology Surveillance Network of Northern France. Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) in northern France: a five-year multicentre incidence study. J Hosp Infect 2002;52:107-13.
18. Jain A, Roy I, Gupta MK, Kumar M, Agarwal SK. Prevalence of extended-spectrum beta-lactamase producing Gram-negative bacteria in septicemic neonates in a tertiary care hospital. J Med Microbiol 2003;52:421-5.
19. Raymond J, Aujard Y. Nosocomial infections in pediatric patients: a European multicenter prospective study. European Study Group. Infect Control Hosp Epidemiol 2000;21:260-3
20. Rebuck JA, Olsen KM, Fey PD, Langnas AN, Rupp ME. Characterization of an outbreak due to extended-spectrum β-lactamase producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis 2000;31:1368-72.
21. Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN, for the Sentry APAC Study Group. Prevalence of extended-spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis 2002;42:193-8.
22. Rupp ME, Fey PD. Extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. Considerations for diagnosis, prevention and drug treatment. Drugs 2003;63:353-65.